171663-13-1

Basic information

• Product Name: TERT-BUTYL 3-BROMOBENZYLCARBAMATE
• Synonyms: (3-BROMO-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER;1-(Boc-aMinoMethyl)-3-broMobenzene;N-Boc-3-broMobenzylaMine;Carbamic acid, N-[(3-bromophenyl)methyl]-, 1,1-dimethylethyl ester;N-[(3-Bromophenyl)Methyl]-Carbamic Acid 1,1-Dimethylethyl Ester;tert-butyl N-[(3-bromophenyl)methyl]carbamate;TERT-BUTYL 3-BROMOBENZYLCARBAMATE
• CAS NO: 171663-13-1
• Molecular Formula: C₁₂H₁₆BrNO₂
• Molecular Weight: 286.16494
• Product Categories: amine|alkyl bromide| carboxylic ester
• Mol File: 171663-13-1.mol

Chemical Properties

• Boiling Point: 370.3 °C at 760 mmHg
• Flash Point: 177.8 °C
• Appearance: /
• Density: 1.319 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: TERT-BUTYL 3-BROMOBENZYLCARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 3-BROMOBENZYLCARBAMATE(171663-13-1)
• EPA Substance Registry System: TERT-BUTYL 3-BROMOBENZYLCARBAMATE(171663-13-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 171663-13-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 3-BROMOBENZYLCARBAMATE is used as a building block for the synthesis of various pharmaceuticals. Its protective role in peptide synthesis allows for the creation of complex drug molecules with specific functionalities, contributing to the development of new and effective medications.
Used in Agrochemical Industry:
In the agrochemical sector, TERT-BUTYL 3-BROMOBENZYLCARBAMATE is utilized as a component in the production of agrochemicals. Its protective capabilities during synthesis processes enable the creation of compounds with targeted effects on pests or crops, enhancing the efficiency and selectivity of these products.
Used in Organic Synthesis:
TERT-BUTYL 3-BROMOBENZYLCARBAMATE is employed as a protective agent in organic synthesis. Its ability to shield specific functional groups during reactions is crucial for the successful synthesis of complex organic compounds, making it an indispensable tool in the field of organic chemistry.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 39959-54-1 3-bromobenzylamine hydrochloride 
• 183735-18-4 2-(3-bromobenzyl)isoindoline-1,3-dione 
• 823-78-9 meta-bromobenzyl bromide 
• 1228693-08-0 C₂₃H₂₁BrF₁₇NO₃ 
• 10269-01-9 3-bromobenzylamine 

Downstream Products

• 1616590-15-8 (4,4-dimethyl-3,4-dihydrocarbostyril)-6-carboxylic acid (E)-3-[2-(hydroxycarbamoyl)vinyl]benzylamide 
• 1616590-17-0 (4,4-dimethyl-3,4-dihydrocarbostyril)-7-carboxylic acid (E)-3-[2-(hydroxycarbamoyl)vinyl]benzylamide 
• 1616590-39-6 C₂₄H₂₆N₂O₄ 
• 1616590-40-9 C₂₄H₂₆N₂O₄ 
• 903556-08-1 C₁₄H₁₈F₃NO₃ 
• 317358-61-5 tert-butyl (3-bromo-benzyl)-N-methylcarbamate 
• 603126-93-8 2-benzenesulfonylamino-3-({5-[3-(tert-butoxycarbonylamino-methyl)-phenyl]-thiophene-2-carbonyl}-amino)-propionic acid tert-butyl ester 

Relevant articles and documents

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

COMPOUNDS AND USES THEREOF

The present disclosure features compounds and methods useful for the treatment of BAF complex-related disorders.

Structure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy

CARM1 is a protein arginine methyltransferase and acts as a transcriptional coactivator regulating multiple biological processes. Aberrant expression of CARM1 has been related to the progression of multiple types of cancers, and therefore CARM1 was consid

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF

Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof or tautomers thereof.

First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate

Inhibition of neuronal nitric oxide synthase (nNOS), an enzyme implicated in neurodegenerative disorders, is an attractive strategy for treating or preventing these diseases. We previously developed several classes of 2-aminoquinoline-based nNOS inhibitor

CHEMICAL COMPOUNDS

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to FormμLa (I): wherein R, R1,P, X, Y, and Z are as defined herein; or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be usefμL in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Arginine methyltransferase inhibitor and pharmaceutical composition and application thereof

The invention relates to an arginine methyltransferase inhibitor and a pharmaceutical composition and application thereof, in particular to a compound represented by a formula (I), a pharmaceuticallyacceptable salt, isomer, racemate, prodrug, co-crystal c

K-RAS MODULATORS WITH A VINYL SULFONAMIDE MOIETY

Provided herein are compounds comprising a vinyl sulfonamide moiety. Also provided herein are pharmaceutical compositions comprising such compounds, and methods of using such compounds and pharmaceutical compositions for inhibiting the post-translational

Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1)

The L-type amino acid transporter 1 (LAT1, SLC7A5) transports essential amino acids across the blood-brain barrier (BBB) and into cancer cells. To utilize LAT1 for drug delivery, potent amino acid promoieties are desired, as prodrugs must compete with millimolar concentrations of endogenous amino acids. To better understand ligand-transporter interactions that could improve potency, we developed structural LAT1 models to guide the design of substituted analogues of phenylalanine and histidine. Furthermore, we evaluated the structure-activity relationship (SAR) for both enantiomers of naturally occurring LAT1 substrates. Analogues were tested in cis-inhibition and trans-stimulation cell assays to determine potency and uptake rate. Surprisingly, LAT1 can transport amino acid-like substrates with wide-ranging polarities including those containing ionizable substituents. Additionally, the rate of LAT1 transport was generally nonstereoselective even though enantiomers likely exhibit different binding modes. Our findings have broad implications to the development of new treatments for brain disorders and cancer.